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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1471Oxidative Stress and Pathological Changes After Coronary Artery InterventionsRio P. Juni, Henricus J. Duckers, Paul M. Vanhoutte, Renu Virmani, An L. Moens
Coronary interventions are associated with increased vascular levels of reactive oxygen species
(ROS) in conjunction with altered function of endothelial and smooth muscle cells. These
alterations potentially lead to restenosis, thrombosis, or endothelial dysfunction in the peri-
stent segment. This review discusses the molecular mechanisms of ROS generation after
coronary interventions, the related pathological events, including restenosis, endothelial
dysfunction, and stent thrombosis, and possible therapeutic ways forward. Current
innovations, including biodegradable stents, nitric oxide donor-coated stents, and a new
generation of drug-eluting stents, are proposed to address the persistent oxidative stress and
reduced nitric oxide bioavailability after percutaneous coronary interventions.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1482Double Kissing Balllon Superior to Culotte Stenting for Distal Left Main LesionsShao-Liang Chen, Bo Xu, Ya-Ling Han, Imad Sheiban, Jun-Jie Zhang, Fei Ye, Tak W. Kwan,
Chitprapai Paiboon, Yu-Jie Zhou, Shu-Zheng Lv, George D. Dangas, Ya-Wei Xu, Shang-Yu Wen,
Lang Hong, Rui-Yan Zhang, Hai-Chang Wang, Tie-Ming Jiang, Yan Wang, Fang Chen, Zu-Yi Yuan,
Wei-Min Li, Martin B. Leon
The DKCRUSH-III study randomized subjects with unprotected left main coronary artery
distal bifurcation lesions to either double kissing (DK) crush or Culotte stenting techniques.
A total of 419 patients were randomly assigned with a primary endpoint of major adverse
cardiac event (MACE) at 1 year. The MACE rate was significantly higher in the Culotte
group, mainly driven by increased target vessel revascularization. In-stent restenosis rate in
side branch was 12.6% in the Culotte group and 6.8% in the DK group. These results
suggest that DK should be the preferred option for left main bifurcation lesions.(continued on page A-30)
APRIL 9, 2013 (continued) A-30VALVE DISEASE1489Outcome of Combined Stenotic and Regurgitant Aortic Valve DiseaseRobert Zilberszac, Harald Gabriel, Michael Schemper, David Zahler, Martin Czerny, Gerald Maurer,
Raphael Rosenhek
The combination of aortic stenosis (AS) and aortic regurgitation (AR) may increase
transvalvular flow interfering with echocardiographic indices of valve function and thus
prognosis. Zilberszac and colleagues reviewed records from 71 consecutive asymptomatic
patients with at least moderate AS in combination with at least moderate AR and preserved
left ventricular function. There were no cardiac deaths during 9 years of follow-up. One-half
of patients with a peak aortic jetvelocity (AV-Vel) between 3 and 3.9 m/s at baseline had
surgery AVR surgery by 6 years, compared to all patients with an AV-Vel 5 m/s. These
results imply that AV-Vel, which reflects both stenosis and regurgitant severity, provides an
objective and easily assessable predictive parameter.Editorial Comment: Benjamin Byrd, Michael Baker, p. 1496HEART FAILURE1498BNP Predicts Mortality Better Than LVEF for Patients With HFDirk J. van Veldhuisen, Gerard C. M. Linssen, Tiny Jaarsma, Wiek H. van Gilst, Arno W. Hoes,
Jan G. P. Tijssen, Walter J. Paulus, Adriaan A. Voors, Hans L. Hillege
van Veldhuisen and colleagues sought to determine the prognostic value of brain natriuretic
peptide (BNP) in patients with heart failure with preserved ejection fraction (HFPEF), in
comparison to heart failure patients with reduced left ventricular ejection fraction (HFREF).
Over 600 patients who had been hospitalized for heart failure (HF) were followed. BNP
levels were significantly higher in patients with reduced (40%) left ventricular ejection
fraction (LVEF). BNP was a strong predictor of outcomes, but ejection fraction was not. For
similar levels of BNP, the prognosis was equivalent for HFPEF patients and those with
HFREF. These results suggest that BNP offers robust and similar prognostic information for
patients with congestive HF regardless of the LVEF.
Editorial Comment: James L. Januzzi, Jr., p. 1507(continued on page A-31)
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Martha L. Daviglus, Donald M. Lloyd-Jones
Huffman and colleagues noticed that prior estimates of lifetime risk for developing heart
failure (HF) did not include sufficient numbers of black patients. Data was combined from
3 large cohort studies to estimate the lifetime risks for developing HF, with death free of HF
as the competing event. At age 45 years, lifetime risks for HF through age 95 years were 30%
to 42% in white men, 20% to 29% in black men, 32% to 39% in white women, and 24% to
46% in black women. The authors noticed higher competing mortality risks from other
diseases or accidents may have lowered the risk in black men. These are among the first data
to compare lifetime risks for HF between blacks and whites.HEART FAILURE
1518Carvedilol Associated With Improved Outcomes
Compared to Metoprolol in the MADIT-CRT PatientsMartin H. Ruwald, Anne-Christine H. Ruwald, Christian Jons, Jeffrey Alexis, Scott McNitt,
Wojciech Zareba, Arthur J. Moss
Ruwald and colleagues reviewed data from all patients receiving either metoprolol or
carvedilol in the MADIT-CRT study, which randomized New York Heart Association
functional class I to II patients with standard implantable cardioverter-defibrillators (ICD)
indications, to either ICD or cardiac resynchronization therapy (CRT). Treatment with
carvedilol was associated with a significantly decreased risk of hospitalization for heart failure
or death when compared to metoprolol (hazard ratio [HR]: 0.70). This reduction in risk was
further attenuated in the subgroup of CRT-D patients (HR: 0.62) and CRT-D patients with
left bundle branch block (HR: 0.51). Although this was not a randomized trial, the results
strongly suggest that carvedilol offers more benefits for these types of patients than metoprolol
does.(continued on page A-32)
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hHEART RHYTHM DISORDERS1527Use of ICDs in Children and Adolescents With HCMBarry J. Maron, Paolo Spirito, Michael J. Ackerman, Susan A. Casey, Christopher Semsarian,
N. A. Mark Estes III, Kevin M. Shannon, Euan A. Ashley, Sharlene M. Day, Giuseppe Pacileo,
Francesco Formisano, Emmanuela Devoto, Aristidis Anastasakis, J. Martijn Bos, Anna Woo,
Camillo Autore, Robert H. Pass, Giuseppe Boriani, Ross F. Garberich, Adrian K. Almquist,
Mark W. Russell, Luca Boni, Stuart Berger, Martin S. Maron, Mark S. Link
Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death (SD) in
the young, but there are limited data on the use of implantable cardioverter-defibrillators
(ICDs) in children and adolescents. Maron and colleagues reviewed a multicenter
international registry of ICDs implanted in 224 children and adolescents with HCM.
Defibrillators activated appropriately to terminate ventricular tachycardia/fibrillation in 19% of
patients, with an appropriate ICD intervention rate of 14%/year for secondary prevention and
3.1% for primary prevention. ICD-related complications, particularly inappropriate shocks and
lead malfunction, occurred in 41% of patients. These results confirm the utility of, and the
risks of, ICDs for children and adolescents with HCM.Editorial Comment: Mark V. Sherrid, p. 1536CARDIAC IMAGING
1539CMR Shows Reduced LV and RV Function But No Fibrosis
After Anthracycline Treatment for Childhood CancerKaisa Ylänen, Tuija Poutanen, Päivi Savikurki-Heikkilä, Irina Rinta-Kiikka, Anneli Eerola,
Kim Vettenranta
The pathogenesis of late-onset cardiac toxicity of anthracyclines remains incompletely
understood, but evidence suggests myocyte apoptosis which should produce myocardial
fibrosis. This fibrosis would be detectable as late gadolinium enhancement (LGE) on cardiac
magnetic resonance (CMR) imaging. Ylänen and colleagues studied 62 anthracycline-exposed
long-term survivors of childhood cancer with CMR approximately 10 years after their
exposure. A left ventricular (LV) ejection fraction (EF) 45% was detected in 18%, and a
urther 61% had an EF 55%, but 45%. Similar rates were seen for right ventricular (RV)
unction. Both the LV and RV end-systolic and LV end-diastolic volumes were increased
ompared to reference values. None of the study patients showed LGE. These results show
igh rates of reduced RV and LV function after anthracycline exposure without LGE.
